

REFERENCES



REFERENCES

- นิโลบล เนื่องต้น. (2539). โปรตีนในเลือดที่สำคัญทางการแพทย์. กรุงเทพฯ: ธรรมสาร.
- สุรศักดิ์ เสาก้าว. (2543). ยากันเลือดแข็งตัว ยาต้านเกล็ดเลือด และยาละลายลิ่มเลือด.
ม.ป.ท.: ม.ป.พ.
- พรวรีย์ ลำเจียกเทศ, กฤษณา ปทีปโชติวงศ์ และพรศรี ตันตินิติ. (2540). การตรวจการห้ามเลือด
ทางห้องปฏิบัติการ. กรุงเทพฯ: โรงพิมพ์เรือนแก้วการพิมพ์.
- Bai, H., Nangia, S. and Parmer, R. J. (2012). The plasminogen activation system and
the regulation of catecholaminergic function. **J Biomed Biotechnol**,
2012(2012), 1-13.
- Benedum, U. M., Baeuerle, P. A., Konecki, D. S., Frank, R., Powell, J., Mallet, J., et al.
(1986). The primary structure of bovine chromogranin A: a representative of
a class of acidic secretory proteins common to a variety of peptidergic cells.
EMBO J, 5(7), 1495-1502.
- Blaschko, H., Comline, R. S., Schneider, F. H., Silver, M. and Smith, A. D. (1967).
Secretion of a chromaffin granule protein, chromogranin, from the adrenal
gland after splanchnic stimulation. **Nature**, 215(5096), 58-59.
- Blaschko, H., Hagen, J. M. and Hagen, P. (1957). Mitochondrial enzymes and
chromaffin granules. **J Physiol**, 139(2), 316-322.
- Borges and L. Gandía (Eds.). **Cell Biology of the chromaffin cell**. Bergen, Norway:
University of Bergen.
- Bruno, T., Anna, M. Q., Valentina, D. F. and Maria, C. C. (2006). New biological
aspects of chromogranin A-derived peptides: Focus on vasostatins.
Comparative Biochemistry and Physiology, 147(1), 11-18.
- Carson, M., Johnson, D. H., McDonald, H., Brouillette, C. and Delucas, L. J. (2007).
His-tag impact on structure. **Acta Crystallogr. D Biol. Crystallogr**, 63(3),
295-301.
- Castañon, M. M., Gamba, C. and Kordich, L. C. (2007). Insight into the
profibrinolytic activity of dermatan sulfate: Effects on the activation of
plasminogen mediated by tissue and urinary plasminogen activators.
Thrombosis Research, 120(5), 745-752.

- Castellino, F. J. and Mc Cance, S. G. (1997). The kringle domains of human plasminogen. **Ciba Found Symp**, 212, 46-60.
- Castellino, F. J. and Ploplis, V. A. (2005). Structure and function of the plasminogen/plasmin system. **Thromb Haemost**, 39(4), 647-654.
- Ceconi, C., Ferrari, R., Bachetti, T., Opasich, C., Volterrani, M., Colombo, B., et al. (2002). Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. **Eur Heart J**, 23(12), 967-974
- Cesarman, M. G. and Hajjar, K. A. (2005). Molecular mechanisms of fibrinolysis. **Br J Haematol**, 129(3), 307-321.
- Collen, D. and Lijnen, H. R. (1991). Basic and clinical aspects of fibrinolysis and thrombolysis. **Blood**, 78(12), 3114-3124.
- Colman, W. R., Marder, J. V., Clowes, W. A., George, N. J. and Goldhaber, Z. S. (2006). **Hemostasis and thrombosis: Basic principles and clinical practice**. USA: Lippincott Williams & Wilkins.
- Colombo, B., Longhi, R., Marinzi, C., Magni, F., Cattaneo, A., Yoo, S. H., et al. (2002). Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. **J Biol Chem**, 277(48), 45911-45919.
- Comerota, J. A. (1995). **Thrombolytic therapy for peripheral vascular disease**, USA. J.B. Lippincott.
- Corti, A. (2004). Chromogranin A in tumor and vascular biology. Milan, Italy: Department of Biological and Technological Research, San Raffaele H Scientific Institute.
- Dudani, A, K. (2000). Plasminogen and tissue plasminogen activator interact with antithrombin III. **Thrombosis Research**, 99(6), 635-641
- Eaton, D., Scott, R. and Baker, J. (1984). Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. **J Biol Chem**, 259(10), 6241-6247.
- Epstein, F. H., Kohler, H. P. and Grant, P. J. (2000). Plasminogen-activator inhibitor type 1 and coronary artery disease. **N Engl J Med**, 342(24), 1792-1801.

- Forsgren, M., Raden, B., Israelsson, M., Larsson, K. and Hedén, L. (1987). Molecular cloning and characterization of a full-length cDNA clone for human lasminogen. **FEBS Letters**, 213(2), 254-260.
- Frand, A. R., Cuozzo, J. W. and Kaiser, C. A. (2000). Pathways for protein disulphide bond formation. **Trends Cell Biol**, 10(5), 203-210
- Gaffney, P. J. and Edgell, T. A. (1996). The international standard for plasminogen activator inhibitor-1 (PAI-1) activity. **Thromb Haemost**, 76(1), 80-83
- Ghia, J., Pradaud, I., Crenner, F., Hélène, M., Boutigue, M., Aunis, D., et al. (2005). Effect of acetic acid or trypsin application on rat colonic motility in vitro and modulation by two synthetic fragments of chromogranin A. **Regulatory Peptides**, 124(1-3), 27-35.
- Harris, R. J., Leonard, C. K., Guzzetta, A. W. and Spellman, M. W. (1991). Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain. **Biochemistry**, 30(9), 2311-2314.
- Helle, K. B. (2010). The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. **Cardiovasc Res**, 85(1), 9-16.
- Bureau of Health Policy and Strategy. (2009). **Number and Death Rates per 100,000 Population of First 10 Leading Cause Groups of Death (According to ICD Mortality Tabulation List1, 10th Revision) 2005 – 2009**. Retrieved May 28, 2011, from http://bps.ops.moph.go.th/E-book/statistic/statistic52/2.3.1_52.pdf
- Karen, B. Hellea and Sushil, K. Mahatab. (2004). **Chromogranin A-derived peptides: functional aspects of vasostatins, pancreastatin, catestatin and parastatin**. Norway: The Department of Biomedicine, University of Bergen.
- Holvoet, P., Lijnen, H. R. and Collen, D. (1985). A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. **J Biol Chem**, 260(22), 12106-12111.
- Hoylaerts, M., Rijken, D. C., Lijnen, H. R. and Collen, D. (1982). Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. **J Biol Chem**, 257(6), 2912-2919.
- Huttner, W.B., Gerdes, H.H. and Rosa, P. (1991). The granin (chromogranin/secretogranin) family. **Trends Biochem Sci**, 16(1), 27-30.

- Inge, M. W. Ebisch., Chris, M. G. Thomas., Alex, M. M. Wetzels., Wim, N. P. Willemsen., Fred, C. G. J. Sweep. and Régine, P. M. Steegers-Theunissen. (2008). Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility. **Fertility and sterility**, 90(6), 2340-2350.
- Indiana Hemophilia & Thrombosis Center. (2012). **Inherited Causes of Thrombosis**. Indianapolis: Indiana Hemophilia & Thrombosis Center.
- Ischia, R., Gasser, R.W. and Fischer-Colbrie, R. (2000). Levels and molecular properties of secretoneurin- immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. **J Clin Endocrinol Metab**, 85(1), 355-360.
- Jiang, Q., Taupenot, L., Mahata, S. K., Mahata, M., O'Connor, D. T., Miles, L. A., et al. (2001). Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. **J Biol Chem**, 276(27), 25022-25029.
- Jiang, Q., Yasothornsrikul, S., Taupenot, L., Miles, L. A. and Parmer, R. J. (2002). The local chromaffin cell plasminogen/plasmin system and the regulation of catecholamine secretion. **Annals of the New York Academy of Sciences**. 971(1), 445-449.
- Konecki, D. S., Benedum, U. M., Gerdes, H. H. and Huttner, W. B. (1987). The primary structure of human chromogranin A and pancreastatin. **J Biol Chem**, 262(35), 17026-17030.
- Kohnert, U., Hellerbrand, K., Martin, U., Stern, A., Popp, F. and Fischer, S. (1996). The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. **Fibrinolysis**, 10(2), 93-102.
- Kumar, A. (2010). Evolutionary trend of thrombolytics. **International Journal of Bio-Science and Bio-Technology**, 2(4), 51-68.
- Lugardon, K., Raffner, R., Goumon, Y., Corti, A., Delmas, A., Bulet, P., et al. (2000). Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. **J Biol Chem**, 275(15), 10745-10753.

- Miles, L. A., Hawley, S. B. and Parmer, R. J. (2002). Chromaffin cell plasminogen receptors. **Annals of the New York Academy of Sciences**, 971(1), 454-459.
- Marie, H., Metz-Boutigue, Pascale Garcia-Sablone, Ruth Hogue, Angeletti and Dominique Aunis. (1993). Intracellular and extracellular processing of chromogranin A determination of cleavage sites. **Eur. J. Biochem**, 217(1), 247-257.
- Modlin, I. Gustafsson, B. Moss, S. Pavel, M. Tsolakis, A. and Kidd, M. (2010). Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. **Ann Surg Oncol**, 17(9), 2427–2443.
- Mouland, A.J., Bevan, S., White, J.H. and Hendy G.N. (1994). Human chromogranin A gene: Molecular cloning, structural analysis, and neuroendocrine cell specific expression. **J Biol Chem**, 269(9), 6918–6926.
- Nagakawa, O., Murakami, K., Ogasawara, M., Murata, J., Fuse, H. and Saiki, I. (1999). Effect of chromogranin A (pancreastatin) fragment on invasion of prostate cancer cells. **Cancer Letters**, 147 (1-2), 207-213.
- Nishino, T., Yamauchi, T., Horie, M., Nagumo, T. and Suzuki, Haruo. (2000). Effects of a fucoidan on the activation of plasminogen by u-PA and t-PA. **ThrombosisResearch**, 99(6), 623-634.
- Nitish, R. and Mahapatra. (2008). Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. **Cardiovascular Research**, 80(3), 330–338.
- Nobels, F.R.E., Kwekkeboom, D.J., Bouillon, R. and Lamberts S.W.J. (1998). Chromogranin A: its clinical value as marker of neuroendocrine tumours. **European journal of clinical investigation**, 28(6), 431-440.
- Novagen. (2003). **Protein expression: Prokaryotic expression**. Retrieved July 3, 2011, from <http://www.yrgene.com/sites/default/files/documents/vector/c183-001.pdf>
- O'Connor, D.T. and Frigon, R. P. (1984). Chromogranin A, the major catecholamine storage vesicle soluble protein. **J Biol Chem**, 259(5), 3237-3247.
- Pallister, C. (1994). **Blood physiology and pathophysiology**. Great Britain: Butterworth- Heinemann.

- Parmer, R. J., Mahata, M., Gong, Y., Mahata, S. K., Jiang, Q., O'Connor, D. T., et al. (2000). Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. **Journal of Clinical Investigation**, 106(7), 907-915.
- Parmer, R. J., Mahata, M., Mahata, S., Sebald, M. T., O'Connor, D. T. and Miles, L.A. (1997). Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. **J Biol Chem**, 272(3), 1976-1982.
- Pernod, G., Aouffen, M., Polack, B., LeMagueresse-Battistoni, B., Benabid, A. L., and Kolodíé, L. (1998). t-PA-dependent activation of C6 glioma-bound plasminogen: a kinetic study. **Fibrinolysis and Proteolysis**, 12(3), 137-144.
- Plow, E. F., Felez, J. and Miles, L. A. (1991). Cellular regulation of fibrinolysis. **Thromb Haemost**, 66(1), 32-36.
- Qin, M., Zhang, J. and Wang, W. (2006). Effects of disulfide bonds on folding behavior and mechanism of the beta-sheet protein tendamistat. **Biophys J**, 90(1), 272-286.
- Rashida, A. (2006). **Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy**. New York: n.p.
- Raum, D., Marcus, D., Alper, C. A., Levey, R., Taylor, P. D. and Starzl, T. E. (1980). Synthesis of Human Plasminogen by the Liver. **Science**, 208(4447), 1036-1037.
- Riddel, J. P., Aouizerat, B. E., Miaskowski, C. and Lillicrap, D. P. (2007). Theories of blood coagulation. **Journal of Pediatric Oncology Nursing**, 24(3), 123-131.
- Rijken, D. C. and Collen, D. (1981). Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. **J Biol Chem**, 256(13), 7035-7041.
- Rijken, D. C., Hoylaerts, M. and Collen, D. (1982). Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. **J Biol Chem**, 257(6), 2920-2925.
- Sambrook, J., Fritsch, E.F. and Maniatis T. (2001). **Molecular cloning: A laboratory manual** (3rd ed.). New York: Cold Spring Harbor Laboratory.

- Schoenmakers, S. H., Reitsma, P. H. and Spek, C. A. (2005). Blood coagulation factors as inflammatory mediators. **Blood Cells, Molecules, and Diseases**, 34, 30–37.
- Simon, J. P. and Aunis, D. (1989). Biochemistry of the chromogranin A protein family. **Biochem J**, 262(1), 1-13
- Skeland, N. L., Zhou, A., Dinh, T. Q., Wu, H., Parmer, R. J., Mains, R. E., et al.(1996) Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. **J Clin Invest**, 98(1), 48-56
- Strub, J.M., Sorokine, O., Van Dorsselaer, A., Aunis, D. and Metz-Boutigue, M.H. (1997). Phosphorylation and O-glycosylation sites of bovine chromogranin A from adrenal medullary chromaffin granules and their relationship with biological activities. **J. Biol. Chem.**, 272(18), 11928–11936.
- Taupenot, L., Harper, K. L. and O'Connor, D. T. (2003). The chromogranin–secretogranin family. **Engl J Med**, 348(12), 1134-1149.
- Tim-uam, A. (2010). **Expression and purification of recombinant human chromogranin A and its variants for proteolytic analysis**. Master thesis, M.S., Naresuan University, Phitsanulok.
- Ugendra, K. (1997). Purification and partial characterization of chromogranin A from human brain. **Biochemistry and molecular biology international**, 41(3), 563– 570
- Yasothornsrikul, S. and Parmer, R. J. (2006). Human Chromogranin A, A potential anti-blood clotting agent. **Proceeding of the 2 nd Naresuan Research Conference**, 1, 39-44.
- Yoo, S H. and Albanesi, J P. (1990). Ca²⁺(+)-induced conformational change and aggregation of chromogranin A. **J. Biol. Chem**, 265(24), 14414–14421.
- Zhang, L., Seiffert, D., Fowler, B. J., Jenkins, G. R., Thinnes, T. C., Loskutoff, D. J., et al. (2002). Plasminogen has a broad extrahepatic distribution. **Thromb Haemost**, 87(3), 493-501.